Literature DB >> 25284854

The First Report of KRT5 Mutation Underlying Acantholytic Dowling-Degos Disease with Mottled Hypopigmentation in an Indian Family.

Shyam Verma1, Sandra M Pasternack2, Arno Rütten3, Thomas Ruzicka4, Regina C Betz2, Sandra Hanneken5.   

Abstract

Galli Galli disease (GGD) is the name given to a rare form of acantholytic Dowling-Degos disease. (DDD), the latter itself being a rare condition. We believe we are describing for the first time in Indian dermatologic literature a case of GGD in a family where 25 persons have DDD and have been able to document a KRT5 mutation in four members of the family. Whereas reticulate pigmentation is a hallmark of DDD there are rare reports of mottled pigmentation with multiple asymptomatic hypopigmented macules scattered diffusely along with the pigmentation. All the cases described here show a mottled pigmentation comprising hypo and hyperpigmented asymptomatic macules. After the clinical diagnosis was made by one of the authors (SV) in India, the German authors repeated histological examination and successfully demonstrated a heterozygous nonsense mutation, c.C10T (p.Gln4X), in exon 1 of the KRT5 gene, from various centers in Munich, Bonn, Dusseldorf and Friedrichschafen in Germany.

Entities:  

Keywords:  Acantholytic Dowling-Degos disease; Galli Galli disease; Indian skin; Keratin 5 mutation; hypopigmentation

Year:  2014        PMID: 25284854      PMCID: PMC4171917          DOI: 10.4103/0019-5154.139884

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


What was known? Only few reports on a distinctive clinical picture in Dowling-Degos disease with hypopigmented macules in Asian and African American patients exist. In a Chinese family with Dowling-Degos disease with hypopigmented macules, the mutation c.C10T in the KRT5 gene had recently been identified.

Introduction

Acantholytic Dowling-Degos disease (DDD) [MIM 179850] (syn. Galli-Galli disease) is a rare genodermatosis which belongs to the spectrum of reticulate pigmentary disorders and is inherited in an autosomal-dominant manner. It classically presents with reticulate pigmentation, usually hyperpigmented macules in combination with hyperkeratotic papules mainly of the flexures;[1] Cases with disseminated monomorphous reddish-brown macules and papules have also been described.[23] Recently, it has been shown that the most common mutation in the keratin 5 (KRT5) gene (c. 418dupA; p.Ile140AsnfsX39) is seen in Galli-Galli disease (GGD) as well as Dowling-Degos disease. Although the clinical picture of both forms is indistinguishable,[4] detection of acantholysis on histopathological evaluation in GGD patients is believed to be the differentiating criterion between GGD and DDD.[5] However, acantholysis can also be found in patients with DDD, supporting the hypothesis that GGD is a variant of DDD.[1] There have been infrequent reports on a distinctive clinical picture in DDD presenting with hypopigmented macules in Asian and African American patients, either with merely hypopigmentation[6] or in combination with the aforementioned reticular pigmentation and erythematous erosive papules with the typical flexural focus.[78] Guo et al. reported on a Chinese family with DDD exhibiting hypopigmented macules along with the well-known typical clinical and histopathological features of DDD and identified a novel heterozygous nonsense mutation, c.10C > T, in exon 1 of KRT5.[7] Wu and Lin presented three patients from one family with clinical and histological DDD along with hypopigmented macules; the histopathological evaluation in one of their patients in papules from the axillary region had features of Galli-Galli disease, however, they did not detect any mutation in KRT5.[8] However, recently, another gene was identified for DDD in two Chinese families, called POFUT1, encoding protein O-fucosyltransferase 1 (Li et al. Am J Hum Genet 2013).[9] We herein describe a family from India with clinical and histopathological features of GGD who exhibit hypopigmentation along with the typical reticular hyperpigmentation and erosive skin colored as well as erythematous papules pronounced on the trunk and flexural areas. At least 25 family members are affected. We performed molecular genetic analyses in several affected family members and identified the heterozygous nonsense mutation c.C10T in the KRT5 gene.

Patients and Methods

Patients

All patients were seen and diagnosed as GGD/DDD by Dr. Shyam Verma in Vadodara, India. The 57-year-old Indian female patient (patient 1) presented with extensive, confluent reticular hyperpigmentation in combination with erythematous macules and skin colored papules pronounced around the neck, decolleté, sternal and submammary region and-to a lesser extent-in the axillary region. Some areas on the trunk had multiple erosions [Figure 1]. Hyperpigmentation was also seen on the extremities and the face. Moreover, she had multiple hypopigmented macules between 3 and 10 mm size distributed symmetrically on her lower abdomen, legs and axillary region. She gave a history of exacerbation of the lesions and itching when exposed to summer heat of her native town and dramatic relief from this in winters and when she went to visit her daughter in United States.
Figure 1

Eroded hyperpigmented lesions of Galli Galli disease with accompanying hypopigmented macules in the index case

Eroded hyperpigmented lesions of Galli Galli disease with accompanying hypopigmented macules in the index case The patient's 32-year-old son (patient 2) showed identical hyperpigmentation on the back of the hands, the face and the extremities; sparse hyperpigmented papules were found in the axillary region. In addition, sharply demarcated hypopigmented macules were symmetrically disseminated over chest, lower abdomen, back and groins [Figures 2 and 3]. The patient's 39-year-old daughter (patient 3) and her 19-year-old granddaughter (patient 4) displayed the same clinical findings as patient 2 [Figure 4]. In addition, patient 3 showed some eroded papules on the lower back and lower abdomen with aggravation and itching during heat and summer. Further history revealed that the skin changes had started in all patients as asymptomatic hyperpigmented and hypopigmented macules after about 15 years of age. Subsequently many of the hyperpigmented macular lesions became raised and keratotic after 45 years of age in patient 1, and after 34 years of age in patient 3 with erosions, burning and aggravation of symptoms occurring during hot and humid climate as well as by sweating.
Figure 2

Predominantly hypopigmented macules scattered diffusely on the trunk in son

Figure 3

Hyperpigmented raised lesions in the axilla with hypopigmented macules on chest and hyperpigmented macules visible on neck of son

Figure 4

Multiple hypo and hyperpigmented macules diffusely scattered on extremities and trunk in daughter

Predominantly hypopigmented macules scattered diffusely on the trunk in son Hyperpigmented raised lesions in the axilla with hypopigmented macules on chest and hyperpigmented macules visible on neck of son Multiple hypo and hyperpigmented macules diffusely scattered on extremities and trunk in daughter

Dermatopathological findings

Dermatohistopathological evaluation of skin biopsies from a hyperpigmented macule from abdomen from patient 1 and a hyperpigmented and hypopigmented macule from patient 2 revealed classic antler like rete ridges, lentiginous hyperplasia in all cases and formation of discrete cleft consistent with GGD in one [Figures 5–7]. Moreover, there was in part a very pronounced pigment incontinency [Figure 6].
Figure 5

Multiple antler like rete ridges with basal cell pigmentation

Figure 7

Mutational analysis for the KRT5 gene

Figure 6

Fusing rete ridges with deeply pigmented basal cell layer and marked pigment incontinence

Multiple antler like rete ridges with basal cell pigmentation Fusing rete ridges with deeply pigmented basal cell layer and marked pigment incontinence Mutational analysis for the KRT5 gene

Molecular genetic analyses

For the molecular genetic analyses, DNA was extracted from four affected individuals from peripheral blood leukocytes according to standard procedures. All coding exons of the KRT5 gene were amplified by PCR of an affected individual (patient 1). The PCR products were purified with the GFX™ PCR DNA Purification Kit (GE Healthcare) and directly sequenced using the BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) on an ABI 3100 genetic analyzer (Applied Biosystems). All patients provided written informed consent, and the investigation was approved by the Ethics Committee of the Medical Faculty of the University of Düsseldorf.

Results and Discussion

By sequencing analysis, we identified a heterozygous nonsense mutation, c.C10T (p.Gln4X), in exon 1 of the KRT5 gene in the index patient (patient 1). Further analyses revealed the same mutation in the son, the daughter and the granddaughter of the index patient (patients 2-4). Additional family members were unfortunately not available for molecular genetic studies. The heterozygous nonsense mutation c.10C > T in KRT5 identified in this study was recently described in a Chinese family with DDD with hypopigmented macules adjacent to the classic lesions showing histological features of DDD.[7] Wu and Lin published a family with reticular hyperpigmentation and hypopigmented macules with DDD with some biopsies showing features on histopathology in accordance with GGD, however, a mutation in KRT5 could not be detected.[8] Upon review of the international dermatologic literature our study seems to be the first mutation report on GGD in patients from India; moreover, the mutation c. 10C > T has so far not been described in the literature for GGD (acantholytic DDD). The detection of this mutation not only in DDD[7] but also in GGD patients gives further confirmation for our hypothesis that GGD is a variant of DDD.[1] In addition, so far there have not been any reports on GGD with hypopigmentation where detection of a mutation in the KRT5 gene has been possible. Further studies have to show if there is a phenotypical correlation between the mutation c.10C > T of KRT5 and GGD resp. DDD with hypopigmentation in Asian patients. On the basis of the present literature, together with the mutation c.10C > T in GGD, five different mutations in KRT5 underlying either GGG or DDD have been described so far, mostly in patients of European origin.[7101112] The understanding of the mechanisms leading to reticulate hyper- and/or hypopigmentation in DDD and GGD is rudimentary at the present time. A single subtype of the hereditary bullous disorder, epidermolysis bullosa simplex (EBS) with hyper- and hypopigmentation, EBS with mottled pigmentation, has been described. Mutations in KRT5 are the underlying cause of EBS with mottled pigmentation.[13] In analogy and terms of a correct terminology, we propose that patients with GGD or DDD clinically displaying hyper and hypopigmentation have to be classified as GGD resp. DDD with mottled pigmentation. Going by existing literature and from the author's personal communications, the latter with mottled pigmentation seems to be a fairly commonly occurring phenotype in the Asian population whereas in publications on Caucasian patients the patients mainly exhibit the reticular phenotype. Keratin 5 constitutes an integral part of the basal cell layer of keratinocytes and thus dominant mutations in KRT5 may play a significant role, besides cell adhesion, in uptake and distribution of melanosomes in keratinocytes.[10] Functional analyses showing that keratins are involved in this process support this hypothesis.[1014] It could be assumed that post-inflammatory hypopigmentation in patients with Fitzpatrick type IV, V or VI leads to the phenotype of GGD or DDD with mottled pigmentation. However, in our patients hypopigmentation occurred without preceding cutaneous inflammation. In addition, postinflammatory pigmentary changes usually regress over time if melanocytes are not destroyed.[15] Permanent hypopigmentation in contrast can be due to the absence or diminution of melanocytes or aberrations in the complex process of melanin synthesis, transport and release to keratinocytes; underlying causes comprise severe cutaneous inflammation[15] or diverse genetic disorders.[16] Future studies have to contribute to the understanding of hyper- and hypopigmentation in reticulate pigment disorders like GGD and DDD in general, as well as with special regard to patients with skin type IV, V and VI, appreciating and further elucidating the notion of a possibly genetically determined ‘individual chromatic tendency’.[17] The idea that hypopigmentation can also be an expression of subclinical acantholysis was suggested in 1995 by Rowley et al. They studied hypopigmented lesions in two patients with dark skin diagnosed with the acantholytic dermatoses, Darier's and Grover's disease and detected acantholytic histopathological features, leading to the hypothesis that the associated leucoderma in those cases became apparent on surrounding dark skin.[18] Also, in our patients reported here, acantholysis was found in hypopigmented lesions. This is what makes it an interesting hypothesis which could possibly be applied to our cases. Moreover, the mechanisms leading to acantholysis in GGD have to be explored further, especially the question whether acantholysis in DDD is indeed rare or is a disregarded or underobserved histopathological feature.[1312] In conclusion, the analyses of our family from India further contribute to the broad and probably origin-related diverging spectrum of clinical symptoms and molecular genetic findings which is expanding steadily in GGD and DDD. The correlation of hypopigmented macules with these genetically determined reticulate pigment disorders is uncommonly reported in literature and is worth studying further, especially with respect to patients with skin type IV, V and VI. A serious consideration needs to be given to the fact that hypopigmented lesions in the Dowling-Degos disease-spectrum may be underreported, a fact emerging from personal communications with several esteemed colleagues from India who have seen coexistence of hypo- and hyperpigmented macules in this disease spectrum. This study also reiterates published observations and discussions suggesting that reticulate pigmentary disorders like DDD, GGD, acropigmentation of Kitamura, acropigmentation of Dohi and Haber's syndrome may have many overlaps clinically.[1920] Further studies will throw more light on whether there are true overlaps between these diseases or whether these entities are placed variably in a continuum under the broad rubric of reticulate pigmentary disorders. Mottled hypopigmentation in addition to the classic signs and symptoms of DDD and GGD may be well recognized over a period of time to be a distinct phenotype in individuals who have dark skin. What is new? We have successfully detected the heterozygous mutation c.C10T in KRT5 in an Indian family with acantholytic Dowling-Degos disease (syn. Galli-Galli disease) with mottled pigmentation. We are highlighting the presence of mottled pigmentation in the reticulate pigmentary disorders of Dowling-Degos disease and Galli Galli disease in patients with Fitzpatrick skin type IV and V. Such reports are rather rare in literature. It is also possible that there is under reporting of mottled pigmentation in this skin type with DDD/GGD.
  20 in total

Review 1.  The expanding spectrum of Galli-Galli disease.

Authors:  Laila El Shabrawi-Caelen; Arno Rütten; Helmut Kerl
Journal:  J Am Acad Dermatol       Date:  2007-05       Impact factor: 11.527

2.  Galli-Galli disease is an acantholytic variant of Dowling-Degos disease.

Authors:  E Sprecher; M Indelman; Z Khamaysi; J Lugassy; D Petronius; R Bergman
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

Review 3.  A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes.

Authors:  Clio Dessinioti; Alexander J Stratigos; Dimitris Rigopoulos; Andreas D Katsambas
Journal:  Exp Dermatol       Date:  2009-06-23       Impact factor: 3.960

Review 4.  Postinflammatory hypopigmentation.

Authors:  V Vachiramon; K Thadanipon
Journal:  Clin Exp Dermatol       Date:  2011-06-14       Impact factor: 3.470

5.  Dowling-Degos disease presenting as hypopigmented macules.

Authors:  Tiffany L Pickup; Diya F Mutasim
Journal:  J Am Acad Dermatol       Date:  2011-06       Impact factor: 11.527

6.  A novel heterozygous nonsense mutation of keratin 5 in a Chinese family with Dowling-Degos disease.

Authors:  L Guo; X Luo; A Zhao; H Huang; Z Wei; L Chen; S Qin; L Shao; J Xuan; G Feng; C Minghua; J Luan; L He; Q Xing
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-05-14       Impact factor: 6.166

Review 7.  The spectrum of reticulate pigment disorders of the skin revisited.

Authors:  Cornelia S L Müller; Lea Tremezaygues; Claudia Pföhler; Thomas Vogt
Journal:  Eur J Dermatol       Date:  2012 Sep-Oct       Impact factor: 3.328

8.  Mutations in POFUT1, encoding protein O-fucosyltransferase 1, cause generalized Dowling-Degos disease.

Authors:  Ming Li; Ruhong Cheng; Jianying Liang; Heng Yan; Hui Zhang; Lijia Yang; Chengrang Li; Qingqing Jiao; Zhiyong Lu; Jianhui He; Jin Ji; Zhu Shen; Chunqi Li; Fei Hao; Hong Yu; Zhirong Yao
Journal:  Am J Hum Genet       Date:  2013-05-16       Impact factor: 11.025

9.  Hypopigmented macules in acantholytic disorders.

Authors:  M J Rowley; L T Nesbitt; P R Carrington; C G Espinoza
Journal:  Int J Dermatol       Date:  1995-06       Impact factor: 2.736

10.  A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease.

Authors:  Haihui Liao; Yiwei Zhao; David U Baty; John A McGrath; Jemima E Mellerio; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2006-08-17       Impact factor: 8.551

View more
  1 in total

1.  Atypical cases of Dowling-Degos disease.

Authors:  Kikkeri Narayanshetty Naveen; Sharatchandra B Athaniker; Spandana P Hegde; Rahul Shetty; Hanumanthayya Radha; Sadashivappa Sangam Parinitha
Journal:  Indian Dermatol Online J       Date:  2016 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.